1-(N,N-dimethylamino)-2-propyl dodecanoate | 79403-22-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-(N,N-dimethylamino)-2-propyl dodecanoate
• 英文别名: lauric-acid dimethylaminopropyl ester；Dodecanoic acid, 2-(dimethylamino)-1-methylethyl ester；1-(dimethylamino)propan-2-yl dodecanoate
• CAS: 79403-22-8
• 化学式: C₁₇H₃₅NO₂
• 分子量: 285.47
• InChiKey: KTPHASGENPMMQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(N,N-dimethylamino)-2-propyl dodecanoate 、 硫酸二乙酯 以 乙醇 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  JP2005/170831

  摘要：

  公开号：
• 作为产物：
  描述：

  月桂酸 、 N,N-二甲基异丙醇胺 生成 1-(N,N-dimethylamino)-2-propyl dodecanoate
  参考文献：
  名称：

  JP2005/170831

  摘要：

  公开号：

文献信息

• Compositions and methods for treatment of premature ejaculation
  申请人：NexMed (Holdings) Inc.

  公开号：US20040241245A1

  公开（公告）日：2004-12-02

  Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C 1 to C 8 alcohol, an aliphatic C 8 to C 30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

  提供了治疗早泄的组合物和方法，其中包括一种含有局部麻醉剂、剪切稀释聚合物增稠剂、选择自脂肪族C1到C8醇、脂肪族C8到C30酯、液态多元醇或其混合物的亲脂成分、水和缓冲系统的组合物，该缓冲系统为组合物提供了在约3至约7.4范围内的缓冲pH值，并将其用于阴茎尿道口。
• Treatment of erectile dysfunction
  申请人：NexMed (Holdings), Inc.

  公开号：US20030220292A1

  公开（公告）日：2003-11-27

  Methods for the treatment of erectile dysfunction are provided comprising placing in the fossa navicularis an amount of a semi-solid vasoactive prostaglandin composition sufficient to increase blood flow in the glans penis and resulting in increased tumescence of the penis. In preferred embodiments, the method further comprises providing erotic stimuli. Another embodiment, the invention provides a method for increasing the tumescence of the glans penis. In another aspect, the invention provides compositions and articles of manufacture for the practice of the methods of the invention.

  本发明提供了治疗勃起功能障碍的方法，包括将半固态血管活性前列腺素组合物的适量放置在龟头海绵窝中，以增加阴茎的血流量并导致阴茎勃起。在优选实施例中，该方法还包括提供性刺激。另一实施例中，本发明提供了一种增加阴茎海绵体勃起的方法。在另一个方面，本发明提供了用于实施本发明方法的组合物和制品。
• Prostaglandin compositions and methods of treatment for male erectile dysfunction
  申请人：NexMed (Holdings), Inc.

  公开号：US20020045665A1

  公开（公告）日：2002-04-18

  The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E 1 composition of a semi-solid consistency, as well as suitable applicators. The composition comprises prostaglandin E 1 , a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C 1 to C 8 alcohol, aliphatic C 2 to C 30 ester, an aliphatic C 8 to C 30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

  本发明提供了治疗勃起功能障碍的方法，其中包括在患者的尿道海绵窝内放置半固体质地的前列腺素E1组合物，以及适当的应用器。该组合物包括前列腺素E1，渗透增强剂，多糖胶，亲脂性化合物和酸性缓冲系统。渗透增强剂是烷基-2-(N,N-二取代氨基)-烷酸酯，(N,N-二取代氨基)-烷醇烷酸酯或这些的混合物。亲脂性化合物可以是脂肪族C1到C8醇，脂肪族C2到C30酯，脂肪族C8到C30酯或这些的混合物。该组合物包括一个缓冲系统，能够为该组合物提供在约3到约7.4的缓冲pH值范围。
• Topical stabilized prostaglandin E compound dosage forms
  申请人：——

  公开号：US20040131664A1

  公开（公告）日：2004-07-08

  Compounds of prostaglandin E group (PGE compounds) are stabilized as non-aqueous compositions that include the compound together with a bulking agent that can be a non-aqueous liquid or a solid in a sheet, film or powder form. The composition can optionally include a skin penetration enhancer. A non-aqueous, solid dosage form comprises a PGE compound substantially uniformly distributed in a carrier sheet or film.

  前列腺素E类化合物（PGE化合物）的复合物被稳定为非水性组合物，其中包括化合物和可作为非水性液体或固体的膨胀剂，可以是薄片、薄膜或粉末形式。该组合物可以选择性地包括皮肤渗透增强剂。非水性固体剂量形式包括在载体薄膜或薄片中均匀分布的PGE化合物。
• Topical compositions containing prostaglandin E1
  申请人：NexMed Holdings, Inc.

  公开号：US06414028B1

  公开（公告）日：2002-07-02

  A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E1. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an acid addition salt of an alkyl-2-(substituted amino)-alkanoate ester, of a (substituted amino)-alkanol alkanoate, or of a mixture thereof. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

  提供了一种适合经皮应用前列腺素E1的半固态一种组成物。该组成物包括前列腺素E1、渗透增强剂、多糖胶、亲脂性化合物和酸性缓冲系统。渗透增强剂是烷基-2-(取代氨基)-烷酸酯的酸性盐、(取代氨基)-烷醇烷酸酯的酸性盐或两者的混合物。亲脂性化合物可以是脂肪族C1至C8醇、脂肪族C8至C30酯或两者的混合物。该组成物包括一个缓冲系统，能够为该组成物提供在约3至约7.4范围内的缓冲pH值。